VSIR and triple-negative breast carcinoma: VISTA expression has also been reported in gastric carcinomas (8,8%), hepatocellular carcinoma (16,4%), triple-negative breast carcinoma (TNBC) (18,5%), human non–small cell lung cancer (21%),pancreatic cancer cells (25,6%) [6, 16, 18–20].